Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
ID Case Conference 21 November 2007 Yvonne Ballard, MD Neutropenic Fever 63yo CM with a history of AML M2, who is admitted on 10/31 for completion of his third cycle of induction. History of Chemotherapy Diagnosed 08/07 08/28/07: Induced with 7+3 09/11/07: BM Bx showed 66% blasts 09/14/07: Re-induced with Capizzi, completed 9/23/07 – Complicated by Neutropenic Fever, PCP Pneumonia, VRE Bacteremia, Coag neg staph Bacteremia. Access replaced three times. 10/24 – 10/27: Re-induced with Capizzi 10/31: Re-admitted to complete induction, completed 11/2/07 Hospital Course 11/2: Completed Chemo, Neutropenic 11/3: Loose BMs, C. diff negative 11/8: Hct drop 25% 12%, SVT, Fevers began (high of 39.6) – Antibiotics began: Vanc, Ceftaz, Levo 11/9: EGD – nonbleeding esophageal erosion; erythematous gastropathy 11/11: Voriconazole added for persistent fever 11/13: ID consulted Medical History PMH: – AML, M2 – Diabetes Mellitus, Type 2 – Hypertension – Hypothyroidism – DJD – Umbilical Hernia Social Hx: – – – – Lives with wife Retired Occ. Etoh No Tobacco, illicits Family Hx: – Mom: HTN – Dad: Accidental death Medications Antibiotics: – Vancomycin 1.25gm IV q8h – Ceftazidime 2gm IV q8h – Voriconazole 350mg po q12h – Bactrim DS MWF – Valtrex 500mg po bid Fluconazole 11/7 - 11/13 Levofloxacin 11/8 - 11/13 Other Meds: – – – – – – Atenolol 50mg daily Lipitor 5mg daily Nexium 40mg bid Finasteride 5mg daily Synthroid 75mcg daily Compazine 10mg tid Allergies: Tobramycin – Rash Physical Exam VS: 36.6 133/74 70 18 98% on RA Gen: WD, WN man comfortable in NAD HEENT: NCAT, alopecia, Perrla, Eomi, Conj pale, sclera anicteric OP with MMM. No overt ulcerations or mucositis. Small, discrete ulcer on the right lateral aspect of the tongue. Dentition is fair, has one dental cary. CV: RRR, Nrml S1S2, No m/g/r Pulm: CTA b/l, No w/r/r Abd: Obese, soft, ND, NT, NABS Ext: 2+ LE pitting edema, nontender Neuro: Nonfocal Skin: No rashes. Multiple normal appearing nevi. The pt has a moderate-sized skin tag on the left neck that appears irritated. Laboratory Data 135 3.7 103 8 28 0.6 72 9.6 1.9 3.4 10.6 <0.1 29 Urinalysis Negative 29.2 ANC 0.0 CXR: Lungs clear Discussion Diagnosis Rothia mucilaginosa Culture Data: 11/8: Blood Culture, periph and PICC – Positive with Rothia mucilaginosa 11/11: Repeat Blood Cultures Negative Rothia mucilaginosa Gram positive cocci Formerly known as Stomatococcus mucilaginosus Classified as a separate genus in the family Micrococcaceae Normally part of flora of the human oral cavity, and upper respiratory tract May be misidentified as Staphylococcus, Micrococcus, or Streptococcus Rothia mucilaginosa Gram positive cocci in clusters, tetrads, or pairs Doesn’t grow on media supplemented with 5% NaCl Non-motile, Non-spore forming Weakly catalase positive Strongly adherent to agar surface Glucose fermenters Mucoid capsule Hydrolizes gelatine and esculin Rothia mucilaginosa Implicated recently in serious infections – Septicemia – Endocarditis – Meningitis – Pneumonia – Osteomyelitis – Peritonitis – Late prosthetic joint infections Rothia mucilaginosa Risk factors for infection include: – Indwelling venous catheter – Leukemia – Cancer – Cardiac Valvular disease – IV Drug abuse – Severe neutropenia » Mucosal damage Literature Review Considered an emerging pathogen as a cause of bacteremia in immunocompromised patients Bacteremia due to Stomatococcus mucilaginosus in neutropenic patients in the setting of a cancer institute Retrospective study of 8 patients with positive blood cultures – All neutropenic (<100 cells/mm3), All fulfilled sepsis criteria – 7/8 had mucositis – 8/8 on prophylactic Ciprofloxacin – 8/8 had Port-A-Cath in place – 5/8 resistant to quinolones – Bacteremia occurred at median time of 6.5 days of neutropenia Review of 566 febrile neutropenic patients: – Stomatococcus the 4th most frequent gram positive bacteremia – Responsible for 5.9% of bloodstream infections Clin Microbiol Infect 2003; 9: 1068-1072. Bacterial Meningitis from Rothia mucilaginosa in Patients with Malignancy or Undergoing Hematopoietic Stem Cell Transplantation Patient #1 – On prophylactic fluconazole, Levofloxacin, and Acyclovir – Fever, Nausea, HA, Mucositis – Initial LP negative, but repeat on Day 23 showed evidence of bacterial infection, and GS positive – Treated with Meropenem and intrathecal Vancomycin – Total tx duration: 6 weeks – Repeat cultures negative Patient #2 – On prophylactic fluconazole, Levofloxacin, and Acyclovir – Malaise, HA, Fever – MS Δs and Fever, Day #18 – LP suggestive of infection – Treated with Ceftazidime, Meropenem, Rifampin, and intrathecal Vancomycin – CSF never cleared – Pt became comatose and eventually died 10 days later Lee et al. Pediatr Blood Cancer 2007; DOI 10.1002/pbc Bacterial Meningitis from Rothia mucilaginosa in Patients with Malignancy or Undergoing Hematopoietic Stem Cell Transplantation 18 total case reports of R. mucilaginosa meningitis – 16 occurred during stem cell transplant – 14 were neutropenic Risk factors identified: – – – – Profound immunocompromise Prophylactic antibiotics Repeated exposure to Broad spectrum antibiotics Mucositis Treatment – All received Vancomycin, 13/18 received 3rd gen. Ceph. – In vitro sensitivities found Rifampin to be most active drug tested, and Ampicillin was the most active β-lactam – 5/8 who received ITV survived Bacteremia Caused by Rothia mucilaginosa in a Patient with Shwachman-Diamond Syndrome 3yr old boy with SDS admitted with fever Positive blood cultures for R.mucilaginosus MIC90 – Rifampin, <0.016 mcg/ml – Erythromycin, <0.016 mcg/ml – Penicillin, 0.05 mcg/ml – Teicoplanin, 0.5 mcg/ml – Vancomycin, 1 mcg/ml – Linezolid 1 mcg/ml – Gentamicin, 3 mcg/ml – Tetracycline, 6 mcg/ml – Amikacin, 8 mcg/ml Vaccher, et al. Infection 2007; 35 (3): 209-210. Bacteremia Caused by Rothia mucilaginosa in a Patient with Shwachman-Diamond Syndrome Patient treated empirically with Unasyn and Netilmicin until cultures returned Pt improved quickly Discharged home after 5 days of Rifampin therapy (15mg/kg/day), and continued for 5 additional days Successful recovery at 2-week follow up Vaccher, et al. Infection 2007; 35 (3): 209-210. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 1995, p. 268–270. Volume 39, No 1